Atenolol and mortality events in patients with chronic kidney disease: Analysis of data from the Japanese Adverse Drug Event Report database

Basic Clin Pharmacol Toxicol. 2022 Apr;130(4):553-556. doi: 10.1111/bcpt.13717. Epub 2022 Feb 23.

Authors

Satoru Mitsuboshi¹, Takahiro Niimura², Fuka Aizawa³, Mitsuhiro Goda⁴, Yoshito Zamami^{2

3}, Keisuke Ishizawa^{2

3}

Affiliations

¹ Department of Pharmacy, Kaetsu Hospital, Niigata, Japan.
² Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
³ Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
⁴ Clinical Research Centre for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

PMID: 35174631
DOI: 10.1111/bcpt.13717

No abstract available

Keywords: adverse event; atenolol; beta-blockers; chronic kidney disease; fatal events.

MeSH terms

Adrenergic beta-Antagonists / adverse effects
Atenolol / adverse effects
Drug-Related Side Effects and Adverse Reactions*
Female
Humans
Hypertension* / chemically induced
Japan / epidemiology
Male
Renal Insufficiency, Chronic* / chemically induced
Renal Insufficiency, Chronic* / drug therapy

Substances

Adrenergic beta-Antagonists
Atenolol

Grants and funding